Alumis, Inc. (ALMS)
23.86
+0.82
(+3.58%)
USD |
NASDAQ |
Aug 25, 15:10
Alumis Total Liabilities (Quarterly) : 108.46M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 108.46M |
| March 31, 2026 | 104.57M |
| December 31, 2025 | 114.84M |
| September 30, 2025 | 103.24M |
| June 30, 2025 | 125.60M |
| March 31, 2025 | 92.98M |
| Date | Value |
|---|---|
| December 31, 2024 | 80.89M |
| September 30, 2024 | 64.17M |
| June 30, 2024 | 64.70M |
| March 31, 2024 | 67.73M |
| December 31, 2023 | 53.50M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 182.93M |
| Aclaris Therapeutics, Inc. | 55.11M |
| Crinetics Pharmaceuticals, Inc. | 129.92M |
| Tarsus Pharmaceuticals, Inc. | 264.41M |
| Structure Therapeutics, Inc. | 71.01M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 560.62M |
| Shareholders Equity (Quarterly) | 452.16M |
| Debt to Equity Ratio | 0.0806 |
| Current Ratio | 6.744 |
| Net Debt Paydown Yield | -0.03% |